Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-275833, 1% · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| SB-275833 ointment, 1% | DRUG | - |
Inclusion criteria: * Must have primary impetigo with total lesion area being 100 square centimeters or less. * Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures. Exclu...
SB-275833 is an investigational small molecule being developed by GSK plc for the treatment of impetigo and other bacterial skin infections. It is formulated as a 1% topical ointment and has been studied in Phase 3 clinical trials.
SB-275833 is being developed by GSK plc, a global biopharma company listed on the New York Stock Exchange under the ticker GSK. The drug is a small molecule formulated as a 1% topical ointment for bacterial skin infections.
SB-275833 is in Phase 3 clinical development. Two Phase 3 trials have been completed, one with 210 participants and another with 520 participants, both evaluating the 1% ointment for impetigo and bacterial skin infections. The drug is investigational and not yet approved.
SB-275833 has been studied in two completed Phase 3 trials: NCT00133848, which enrolled 210 participants with impetigo across India, Italy, Mexico, Netherlands, and Peru, and NCT00133874, which enrolled 520 participants with bacterial skin infections across multiple countries including Canada, France, Germany, and South Africa.
No, SB-275833 is an active drug, not a placebo. In clinical trials, it was compared against a topical placebo ointment to evaluate its efficacy in treating impetigo. The trials were randomized and double-blind, meaning neither participants nor investigators knew who received the active drug.